Startup
Every investor coverage indicates participated in a round Gene-S raised.
| Investor | Rounds | Invested |
|---|---|---|
| Centre for Entrepreneurial Research and Innovation (CERI) | Accelerator | - |
| Purpose Ventures | Unnamed stage | - |
| Western Australian government | Accelerator | - |
Companies Gene-S acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Gene-S. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A new precision-medicine company formed by Perth's Syngenis Labs, a research institute and two scientists has bought Gene S, maker of the Rosa pharmacogenomics tool; no price was disclosed.
Perth backer Purpose Ventures has added follow-on money to WA care platform PlanCare, taking its seed funding to $2.5 million; the firm's $45 million fund has now backed four startups.
WA's Purpose Ventures has put more money into Plancare, a self-managed healthcare platform, lifting its cumulative backing to $2.5 million; the article also profiles the fund's founders, portfolio and history.
Also Startup Daily
WA VC fund Purpose Ventures has taken on genetic testing startup Gene S as its fourth investment; earlier 2023 backing of PlanCare, Paperly and IDEAcademy is recalled, and the fund's $45m size noted.
WA's New Industries Fund is backing 34 home-grown ventures with over $643,000 in Innovation Booster Grants, most receiving up to $20,000 for commercialisation support, with four funded via a life sciences stream.